Læknablaðið : fylgirit - 01.05.1978, Side 76

Læknablaðið : fylgirit - 01.05.1978, Side 76
O. Strandberg, M. D. , Department of Rheuma- tology, Danderyd Hospital, Sweden. Elisabeth Wijnbladh, M. D., Saltsjöbaden Hospital, Stockholm, Sweden. FerastralW, Astra 2152, is a sterile solution of a complex of iron and a sorbitol glueonic acid polymer, containing 50 mg Fe+++/ml. The preparation can be used in relatively large doses (500 mg) with 3-7 day's interval (Andersson, Grafford, 1975, Swedberg, 1975). In this study, 15 patients with moderate anaemia and subnormal MCHC were treated with Ferastral. In all the patients inflammatory processes, in most cases active rheumatoid arthritis, was the underlying cause. Diagnostic criteria according to American Rheumatism Association were fulfilled. Concomitant therapy consisted of usual anti-inflammatory drugs, such as salicylates, indomethacin, naproxene, and in some cases very low doses of penicillamine. Local therapy with corticosteroids íh very small doses was also used in some cases. The corticosteroid doses thus given were too small to affect the haematopoetic system (Strandberg, 1966). The total doses in mg were estimated by multiplying the haemoglobin deficit in mg/100 ml. by 225 (Brown & Moore, 1956) plus 500 mg for the iron stores. Another method to estimate the expected total iron dose to be given is to multiply desired haematocrit rise by 100 (Mc Curdy, 1970). The total doses given ranged between 1250 mg and 3500 mg, the major part of the patients receiving about 2000 mg. It was given in single doses of 500 mg with an interval of about one week. 3 patients received lower single doses of 250 and 100 mg. Laboratory methods: Haemoglobin was determined by the cyan methaemoglobin method. Erythrocytes were counted in a Coulter counter, and the packed cell volume was determined after 5 minutes centrifuga- tion in a haematocrit centrifuge. Serum iron concentration was determined according to Heil- meyer and Plötner (1937) and UIBC according to Cartwright and Wintrobe (1949). Agarose gel electrophoresis according to H Johansson (1972). Serum albumin concentration according to Doumas (1971) and haptoglobin (Tai-ukoski, 1966) were determined with chemical methods. Alpha-1- FERESTRAL IN THE TREATMENT OF PATIENTS WITH INF LAMMATORY ANAEMIA trypsine, orosomucoid, C'3, C’4 complement fractions, immune globulins G, A, M and trans- ferrin were determined with electro immune assay (Laurell 1972). R esults : The haemoglobin data during the observation period and at least 6 weeks after the start of the trial - the majority of the patients were followed for 8-12 weeks - have been tabulated in every detail, but are not discussed in detail. The statistical treatment of the pertinent data are tabulated (table 2). Every patient served as in its own control and the t-value for the differences between the means for 4 and 8 weeks and the means at the beginning of treatment were calculated. The haemoglobin concentration rose after 8 weeks significantly (P < 0.001) from 109.2 to 122.6 g/1. Although the means for the packed cell volumes displayed a rising tendency, the differences 4 and 8 weeks after the last injection were not statisti- cally significant. The erythrocyte count rose from 4.06 to 4.24 x 106/mm3 (0.1 > P > 0.01). The MCHC means rose from 317 to 334 g/1 (0.01> P> 0.001) at 8 weeks and after 4 weeks from 317 to 324 (0.1 > P > 0.01). The mean serum iron concentration beginning with 40.4 mg/100 ml rose to 68.9 (0. 01 > P> 0.001). The UIBC decreased from 279.3 to 171.8 mg/ml (0.01> P> 0.001). In the small series of trans- ferrin determinations, the same tendency as for UBBC was obtained. The mean decreased from 1.95 to 1.40 g/1 after 8 weeks (0.1 > P> 0. 01). No changes were obtained in the agarose electrophoresis pattern, nor in the serum protein components. Only C’4 showed slightly rising tendency, from 0.16 to 0.20 g/1 (0.1> P > 0. 01). Liver and kidney tests were followed during the test period, without changes (Add. No. 8). Side effects: A brownish discolouration at the injection site was observed in 8/17 patients receiving this iron 74
Side 1
Side 2
Side 3
Side 4
Side 5
Side 6
Side 7
Side 8
Side 9
Side 10
Side 11
Side 12
Side 13
Side 14
Side 15
Side 16
Side 17
Side 18
Side 19
Side 20
Side 21
Side 22
Side 23
Side 24
Side 25
Side 26
Side 27
Side 28
Side 29
Side 30
Side 31
Side 32
Side 33
Side 34
Side 35
Side 36
Side 37
Side 38
Side 39
Side 40
Side 41
Side 42
Side 43
Side 44
Side 45
Side 46
Side 47
Side 48
Side 49
Side 50
Side 51
Side 52
Side 53
Side 54
Side 55
Side 56
Side 57
Side 58
Side 59
Side 60
Side 61
Side 62
Side 63
Side 64
Side 65
Side 66
Side 67
Side 68
Side 69
Side 70
Side 71
Side 72
Side 73
Side 74
Side 75
Side 76
Side 77
Side 78
Side 79
Side 80
Side 81
Side 82
Side 83
Side 84
Side 85
Side 86
Side 87
Side 88
Side 89
Side 90
Side 91
Side 92
Side 93
Side 94
Side 95
Side 96
Side 97
Side 98
Side 99
Side 100
Side 101
Side 102
Side 103
Side 104
Side 105
Side 106
Side 107
Side 108
Side 109
Side 110
Side 111
Side 112
Side 113
Side 114
Side 115
Side 116
Side 117
Side 118
Side 119
Side 120
Side 121
Side 122
Side 123
Side 124
Side 125
Side 126
Side 127
Side 128
Side 129
Side 130
Side 131
Side 132
Side 133
Side 134
Side 135
Side 136
Side 137
Side 138
Side 139
Side 140
Side 141
Side 142
Side 143
Side 144
Side 145
Side 146
Side 147
Side 148
Side 149
Side 150
Side 151
Side 152
Side 153
Side 154
Side 155
Side 156
Side 157
Side 158

x

Læknablaðið : fylgirit

Direkte link

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið : fylgirit
https://timarit.is/publication/991

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.